% | $
Quotes you view appear here for quick access.

InterMune, AŞ Message Board

  • sammyshortcrusha sammyshortcrusha Feb 2, 2009 5:00 PM Flag

    Showtime tomorrow am

    InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
    - Conference Call and Webcast Scheduled -

    * Monday February 2, 2009, 4:50 pm EST

    * Yahoo! Buzz
    * Print


    * InterMune Inc.

    BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN - News) today announced that it will report results from its Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior to market open on Tuesday, February 3. InterMune will conduct a conference call and webcast, with accompanying slide presentation, to discuss results from the CAPACITY program at 8:00 a.m. EST (5:00 a.m. PST) on Tuesday, February 3.

    G/L Sammy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "The smoking gun is the slide show. On positive results, companies give out as little data as possible. They give out some p values and save the meat for a scientific venue. "

      That's bulldinkie. I've seen plenty of results come out, good and bad. Very rarely, they cut a negative conclusion short. Mostly, there's plenty of color given, good news or bad. Agreed, they 'sanitize' the presentation more of the time if results are good. But that just amounts to the same slides with the axes unlabeled.

      What to expect? Best predictor is the Shionogi results--positive, but not dramatic enough to light a fire under FDA. So I agree that the stock price is likely to go down.

    • read 8 weeks

    • I guess devil is in the details 4 cycles of one week plus week of pause in between equals 7 weeks, so if we count 7 weeks to complete the study with last patient will take this study to March 28st. First half of the year ends on June 30th.

      There is also a difference about calling it three months if study was completed in November. I would say 2 months which is pretty standard to amount of secondary points to collect and analyze.

    • There is a big difference between completing enrollment and completing the trial with the last patient visit.

    • ITMN has couple bad releases in 2007, 2006, perhaps it is grasping but I didn't see any announcements to discuss results of canceled trials and not meeting endpoints.
      It would be simpler to face a fiasco in a dark room than in a conference room. Anyone who deals with public would avoid that at any price.

    • Odyd12, I agree, checkout Synta(SNTA) pr release today, they completed enrollment in their phase 3 "SYMMETRYSM" trial, data expected in May, and they have a major partner in GSK.

    • I think there is definitely very little reason to use slide show to show poor results. I would say that slide show will help with some mix points but that is about it, if data is poor I think the words will do the telling.
      From the very beginning Intermune stated that news will be in January, second business day in Feb I say they met their expectations. As to 3 months, I am curious if you done the analysis on your statement, just check Arena, Cypress, Progenies and many other companies how they release data, 3 months is actually average.

    • Too many things to look at. ITMN traditionally releases news this way so I should not read anything to value of the release.
      Bad assumption on my part.

    • going to be interesting, thats for sure